WOCKPHARMA
Wockhardt Limited (WOCKPHARMA) Stock Analysis
Wockhardt Limited is an Indian pharmaceutical company with a global footprint in generics, biologics, and branded markets. It manufactures APIs and formulations including anti-infectives and novel programmes from plants in India and the UK. Wockhardt is known for research in antibiotics and vaccines. It is listed on the NSE and BSE.
Healthcare › Drug Manufacturers - Specialty & Generic
₹1,996.40
-4.20% 1W | +43.10% 52W
Market Cap
32.4k CR
P/E Ratio
79.3
52W High
₹2422.3
52W Low
₹1086.7
Div. Yield
0%
Beta
1
50 DMA
₹2039.9
200 DMA
₹1674.6
Profit Margin
11.2%
Inst. Own.
13.4%
📊 CONSOLIDATION
⚡ APPROACHING SUPPORT
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 644 | 753 | 701 | 700 | 739 | 809 | 721 | 743 | 738 | 782 | 888 | 965 | 929 |
| Expenses | 628 | 681 | 664 | 759 | 648 | 699 | 593 | 679 | 666 | 604 | 711 | 740 | 737 |
| Operating Profit | 16 | 72 | 37 | -59 | 91 | 110 | 128 | 64 | 72 | 178 | 177 | 225 | 192 |
| OPM % | 2.5% | 10% | 5% | -8% | 12% | 14% | 18% | 9% | 10% | 23% | 20% | 23% | 21% |
| Other Income | 0 | 24 | 8 | 10 | 30 | 9 | 8 | 15 | -77 | 21 | 15 | 67 | 31 |
| Interest | 79 | 76 | 77 | 73 | 73 | 73 | 60 | 48 | 48 | 55 | 60 | 50 | 52 |
| Depreciation | 55 | 55 | 55 | 58 | 54 | 55 | 55 | 53 | 56 | 53 | 65 | 53 | 55 |
| Profit before tax | -118 | -35 | -87 | -180 | -6 | -9 | 21 | -22 | -109 | 91 | 67 | 189 | 116 |
| Tax % | 15% | 109% | -1% | -2% | 167% | 78% | 5% | 105% | -1% | 10% | 9% | 13% | 8% |
| Net Profit | -136 | -73 | -86 | -177 | -16 | -16 | 20 | -45 | -108 | 82 | 61 | 164 | 107 |
| EPS in Rs | -9.30 | -5.34 | -5.76 | -11.02 | -0.91 | -1.43 | 0.86 | -1.54 | -5.54 | 4.80 | 3.63 | 10.22 | 6.52 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,482 | 4,453 | 4,015 | 3,937 | 3,566 | 2,844 | 2,708 | 3,230 | 2,651 | 2,798 | 3,012 | 3,373 | 3,564 |
| Expenses | 3,772 | 3,959 | 4,002 | 3,935 | 3,604 | 2,725 | 2,771 | 2,932 | 2,549 | 2,707 | 2,619 | 2,721 | 2,792 |
| Operating Profit | 709 | 494 | 13 | 2 | -38 | 119 | -63 | 298 | 102 | 91 | 393 | 652 | 772 |
| OPM % | 16% | 11% | 0.3% | 0.1% | -1.1% | 4.2% | -2.3% | 9% | 3.9% | 3.2% | 13% | 19% | 22% |
| Other Income | 67 | 66 | 114 | -238 | 116 | 133 | 975 | -163 | -173 | 17 | 62 | 26 | 134 |
| Interest | 55 | 129 | 225 | 255 | 265 | 276 | 249 | 299 | 302 | 305 | 254 | 213 | 217 |
| Depreciation | 145 | 142 | 149 | 150 | 164 | 224 | 246 | 247 | 251 | 223 | 217 | 227 | 226 |
| Profit before tax | 575 | 289 | -247 | -641 | -351 | -247 | 417 | -411 | -624 | -420 | -16 | 238 | 463 |
| Tax % | 28% | 13% | -9% | 4% | -38% | -82% | -65% | -32% | -0% | 12% | 256% | 16% | |
| Net Profit | 413 | 252 | -226 | -667 | -217 | -43 | 688 | -279 | -621 | -472 | -57 | 199 | 414 |
| EPS in Rs | 28.30 | 17.45 | -13.62 | -42.30 | -13.52 | -4.81 | 47.64 | -16.94 | -38.80 | -30.18 | -2.89 | 13.11 | 25.17 |
| Dividend Payout % | 54% | 0% | -56% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 8.0% | 4.0% | -3.0% |
| Profit CAGR | 43.0% | -19.0% | 1.0% |
Shareholding Pattern
Promoters49.09%
FIIs7.29%
DIIs11.00%
Public32.60%
Promoters49.09%
FIIs7.10%
DIIs11.00%
Public32.79%
Promoters49.09%
FIIs7.00%
DIIs10.55%
Public33.36%
Promoters49.09%
FIIs7.09%
DIIs10.96%
Public32.84%
Promoters49.09%
FIIs7.23%
DIIs9.24%
Public34.44%
Promoters59.31%
FIIs2.78%
DIIs0.22%
Public37.70%
Promoters51.60%
FIIs5.49%
DIIs4.82%
Public38.06%
Promoters49.09%
FIIs6.82%
DIIs10.58%
Public33.50%
Promoters49.09%
FIIs7.09%
DIIs10.96%
Public32.84%
Promoters49.09%
FIIs7.23%
DIIs9.24%
Public34.44%
WOCKPHARMA
Holdings Analysis
Key strengths & risk signals
58
Overall
40
Fundamental
76
Technical
Risks (3)
Cannot calculate PEG - insufficient growth data.
RECOVERY MODE! Current price (1996.4) above 200-day but below 50-day.
WEAK MOMENTUM! Limited price growth - -4.2% (1 week), -11.2% (1 month), 10.3% (3 months).
Strengths (3)
BULLISH TREND! 50-day average (2039.9) is above 200-day average (1674.6) - positive signal.
GOOD YEAR! Stock gained 43.1% in the last year.
BULLISH SENTIMENT! In last 30 days: 14 up days, 16 down days. Avg volume on up days: 1,720,655 vs down days: 798,750. Ratio: 2.15x
Fundamental & Technical Analysis
58Overall
40Fundamental
76Technical
Fundamental Breakdown
Growth Quality
10/30
Revenue CAGR: 7.8% (MODERATE, 8/15). Profit CAGR: 0% (DECLINING, 2/15).
Profit Margin
5/10
DECENT EFFICIENCY! 11.2% profit margin - acceptable profitability.
PEG Valuation
0/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
8/10
LOW DEBT! D/E of 0.43 - strong balance sheet.
Public Holding
10/20
SIGNIFICANT PUBLIC HOLDING! 38.83% public ownership - moderate retail influence.
Stability Index
4/10
CAREFUL! Company does not have stable profit track. 2 loss-making quarters detected.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (2039.9) is above 200-day average (1674.6) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (1996.4) above 200-day but below 50-day.
Trend Pattern
10/20
Current trend: CONSOLIDATION
52W Performance
10/10
GOOD YEAR! Stock gained 43.1% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 14 up days, 16 down days. Avg volume on up days: 1,720,655 vs down days: 798,750. Ratio: 2.15x
RSI
3/5
NEUTRAL! RSI at 42.7 - balanced momentum.
52W Range
4/5
UPPER HALF! Trading at 68.1% of 52W range - positive territory.
Momentum
2/5
WEAK MOMENTUM! Limited price growth - -4.2% (1 week), -11.2% (1 month), 10.3% (3 months).
Beta
3/5
MARKET ALIGNED! Beta of 1.00 - moves with the market.
WOCKPHARMA
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q4FY262026-06-11 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WOCKPHARMA | ₹1,996.40 | 79.3 | 11.2% | 7.8% | – | +43.1% | 58 | CONSOLIDATION | -217.8% | -36.1% | +25.9% | -3.7% |
| EMCURE | ₹1,833.50 | 34.4 | 10.4% | 15.4% | 20.2% | +34.8% | 81 | BREAKDOWN | +42.0% | +20.8% | +22.8% | +4.5% |
| NEULANDLAB | ₹20,890.00 | 53.8 | 21.0% | 18.5% | 30.6% | +28.8% | 73 | BREAKDOWN | +962.6% | -30.6% | +119.1% | -17.4% |
| PPLPHARMA | ₹196.90 | – | -3.4% | 7.6% | – | -2.6% | 57 | BOUNCE FROM SUPPORT | -15.1% | +688.6% | +17.4% | -17.5% |
| GRANULES | ₹815.20 | 30.3 | 11.8% | 5.9% | 4.8% | +48.7% | 64 | CONSOLIDATION | +59.9% | -10.7% | +21.2% | +0.5% |
| AJANTPHARM | ₹3,410.10 | 37.6 | 19.6% | 13.4% | 21.6% | +41.1% | 76 | BREAKDOWN | +30.9% | +25.3% | +24.8% | +14.4% |
| IPCALAB | ₹1,915.40 | 37.1 | 12.9% | 15.5% | 34.3% | +45.3% | 84 | BOUNCE FROM SUPPORT | +72.3% | +34.4% | +20.8% | +16.7% |
| GLAND | ₹3,061.80 | 44.7 | 16.8% | 21.3% | 9.6% | +63.8% | 83 | BREAKOUT | +47.1% | -13.6% | +19.6% | +3.3% |
Data from TradeAlone · Updated daily
WOCKPHARMA News
Wockhardt Limited Launches Wockhardt Antibiotic Academy to Combat Antimicrobial Resistance2026-08-10Wockhardt Limited (wockpharma) Reports Q1 FY27: PAT of Rs. 107 Cr, Revenue Up 26%2026-08-10Wockhardt Limited (WOCKPHARMA) shows pressure after breakout, falls 5% intraday2026-08-10Wockhardt Limited (WOCKPHARMA) breaks out, moves up 5% intraday2026-06-17Wockhardt Limited (wockpharma): Innovation, Performance, and Growth Highlighted in Investor Conference2026-06-04Wockhardt Limited Receives U.S. FDA Approval for Zaynich™, a Novel Intravenous Antibiotic2026-05-30Wockhardt Limited Announces CDSCO Approval for Zaynich® Antibiotic2026-05-28Wockhardt Limited Posts Strong FY 26 Financials2026-05-04
